Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

Huang, YD; Karuna, S; Carpp, LN; Reeves, D; Pegu, A; Seaton, K; Mayer, K; Schiffer, J; Mascola, J; Gilbert, PB

Gilbert, PB (reprint author), Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N, Seattle, WA 98109 USA.; Gilbert, PB (reprint author), Univ Washington, Dept Biostat, 1705 NE Pacific St, Seattle, WA 98195 USA.

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018; 14 (9): 2116

Abstract

The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索